Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model - PubMed (original) (raw)

Affiliations

PMID: 10319991

Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model

J M Jones et al. Cell Growth Differ. 1999 Apr.

Abstract

The p21(WAF1/cIP1) cyclin-dependent kinase (cdk) inhibitor is a regulator of the G(1)-S cell cycle checkpoint. Despite the importance of p21 in cell cycle inhibition, its role as a tumor suppressor is uncertain. p21 mutations are infrequent in human tumors, and p21 null mice exhibit no increased tumor incidence. To ascertain whether p21 could influence tumor formation or progression in the context of other oncogenic stimuli, we crossed p21-deficient mice with mammary tumor susceptible Wnt-1 transgenic mice. The p21+/+, p21+/-, and p21-/- Wnt-1 transgenic female offspring were monitored for mammary tumor incidence and growth rates. p21 status had no effect on the age at which mammary tumors formed. However, p21+/- mammary tumors grew significantly faster than p21+/+ and p21-/- mammary tumors. The increased growth rates were confirmed by mitotic index counts and by BrdUrd labelling assays, indicating that a significantly higher percentage of p21+/- tumor cells were in S phase and mitosis than their p21+/+ and p21-/- counterparts. Moreover, cyclin D1-associated phosphorylation of retinoblastoma protein was significantly increased in p21+/- tumor lysates compared with p21+/+ and p21-/- lysates. These results are consistent with data indicating that reduced levels of p21 can facilitate cyclin/cdk complex formation while enhancing cdk activity. Thus, a reduction of p21 dosage may promote tumor progression in the presence of other oncogenic initiators. The dependence of p21 on prior oncogenic stimuli for its tumor-promoting activities suggests that it may behave as a tumor modifier gene rather than as a tumor suppressor gene.

PubMed Disclaimer

Cited by

Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.
Sasamori H, Nakayama K, Razia S, Yamashita H, Ishibashi T, Ishikawa M, Sato S, Nakayama S, Otsuki Y, Fujiwaki R, Ishikawa N, Kyo S. Sasamori H, et al. Curr Oncol. 2022 May 18;29(5):3658-3667. doi: 10.3390/curroncol29050294. Curr Oncol. 2022. PMID: 35621684 Free PMC article.
PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D, Usubutun A. Ates Ozdemir D, et al. Pathol Oncol Res. 2016 Jul;22(3):593-9. doi: 10.1007/s12253-016-0040-2. Epub 2016 Jan 21. Pathol Oncol Res. 2016. PMID: 26797858
Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment.
Nassim R, Mansure JJ, Chevalier S, Cury F, Kassouf W. Nassim R, et al. PLoS One. 2013 Jun 17;8(6):e65257. doi: 10.1371/journal.pone.0065257. Print 2013. PLoS One. 2013. PMID: 23799002 Free PMC article.
Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma.
Hukkelhoven E, Liu Y, Yeh N, Ciznadija D, Blain SW, Koff A. Hukkelhoven E, et al. J Biol Chem. 2012 Nov 9;287(46):38523-30. doi: 10.1074/jbc.M112.366542. Epub 2012 Sep 24. J Biol Chem. 2012. PMID: 23007395 Free PMC article.
Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IeM. Wu CH, et al. Int J Gynecol Pathol. 2012 Jul;31(4):297-303. doi: 10.1097/PGP.0b013e31823f8482. Int J Gynecol Pathol. 2012. PMID: 22653341 Free PMC article.

Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model - PubMed (original) (raw)